Whittier Trust Co. Grows Stake in Axon Enterprise, Inc. (NASDAQ:AXON)

Whittier Trust Co. grew its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 5.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 15,820 shares of the biotechnology company’s stock after acquiring an additional 756 shares during the quarter. Whittier Trust Co.’s holdings in Axon Enterprise were worth $6,321,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in AXON. Blue Trust Inc. grew its stake in Axon Enterprise by 987.5% during the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after buying an additional 79 shares during the last quarter. Trivant Custom Portfolio Group LLC purchased a new position in Axon Enterprise during the 1st quarter worth approximately $31,000. Quent Capital LLC grew its stake in Axon Enterprise by 1,875.0% during the 3rd quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock worth $32,000 after buying an additional 75 shares during the last quarter. Asset Dedication LLC purchased a new position in Axon Enterprise during the 2nd quarter worth approximately $47,000. Finally, Friedenthal Financial purchased a new position in Axon Enterprise during the 3rd quarter worth approximately $51,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Insider Buying and Selling

In related news, CEO Patrick W. Smith sold 80,300 shares of Axon Enterprise stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the completion of the transaction, the chief executive officer now directly owns 3,015,366 shares of the company’s stock, valued at approximately $1,121,052,771.48. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director Matthew R. Mcbrady sold 2,000 shares of the business’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $364.66, for a total value of $729,320.00. Following the completion of the transaction, the director now directly owns 4,892 shares of the company’s stock, valued at $1,783,916.72. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Patrick W. Smith sold 80,300 shares of the business’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $371.78, for a total value of $29,853,934.00. Following the completion of the transaction, the chief executive officer now directly owns 3,015,366 shares of the company’s stock, valued at approximately $1,121,052,771.48. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 371,172 shares of company stock valued at $137,000,162. 6.10% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Barclays raised their price target on Axon Enterprise from $381.00 to $387.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Needham & Company LLC reiterated a “buy” rating and issued a $400.00 target price on shares of Axon Enterprise in a research note on Wednesday, August 7th. Northland Securities lifted their target price on Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Bank of America assumed coverage on Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $380.00 target price on the stock. Finally, Jefferies Financial Group assumed coverage on Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $385.00 target price on the stock. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $365.38.

Axon Enterprise Stock Up 1.4 %

AXON opened at $443.98 on Tuesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. The business has a 50 day simple moving average of $388.71 and a 200-day simple moving average of $331.95. The stock has a market capitalization of $33.55 billion, a P/E ratio of 117.15, a P/E/G ratio of 11.74 and a beta of 0.94. Axon Enterprise, Inc. has a 12 month low of $199.29 and a 12 month high of $444.16.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.18. The firm had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. Axon Enterprise’s revenue was up 34.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.80 earnings per share. On average, equities analysts anticipate that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.